Why Early QC Planning Matters in Cell and Gene Therapy - Top-Institutions - MDSpire

Why Early QC Planning Matters in Cell and Gene Therapy

Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes

  • By

  • Laurent Claisse

  • June 30, 2026

  • 9 min

Share

Top Institutions

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology
    • Cell and Gene Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology
    • Cell and Gene Therapy

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center

    Seattle, Washington

    Key Differentiators

    • Hematology
    • Oncology
    • Cell and Gene Therapy

  • #5

    Children’s Research Institute
    Children’s Research Institute

    Washington, District of Columbia

    Key Differentiators

    • Pediatrics
    • Hematology
    • Oncology

Original Source(s)

Why Early QC Planning Matters in Cell and Gene Therapy

  • by Laurent Claisse

  • June 30, 2026

Related Content

The effect of weather on unscheduled healthcare utilisation for mental health conditions in England, 2014–2022

FDA Issues CRL for Oxylanthanum Carbonate

The action relates to previously identified third-party manufacturing deficiencies rather than concerns about the clinical efficacy or safety data, according to the company.

The Retina’s Lost Lipid Signal

High-resolution metabolomics identifies erucamide depletion in retinal degeneration and links restoration to neurovascular rescue

  • June 30, 2026

  • 2 min